

Edgar Filing: AMGEN INC - Form S-8

AMGEN INC  
Form S-8  
January 24, 2002

As filed with the Securities and Exchange Commission on January 24, 2002  
Registration No. 333-

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM S-8  
REGISTRATION STATEMENT UNDER  
THE SECURITIES ACT OF 1933

AMGEN INC.

(Exact name of registrant as specified in its charter)

DELAWARE  
(State or other jurisdiction  
of incorporation or organization)

95-3540776  
(I.R.S. Employer  
Identification No.)

One Amgen Center Drive  
Thousand Oaks, California  
(Address of Principal Executive Offices)

91320-1789  
(Zip Code)

Amgen Nonqualified Deferred Compensation Plan

(Full title of the plan)

STEVEN M. ODRE, ESQ.  
Senior Vice President, General Counsel and Secretary  
Amgen Inc.

One Amgen Center Drive  
Thousand Oaks, California 91320-1789  
(Name and address of agent for service)  
(805) 447-1000  
(Telephone Number, Including Area Code, of Agent For Service)

Copy to:  
GARY OLSON, ESQ.  
Latham & Watkins  
633 West Fifth Street, Suite 4000  
Los Angeles, California 90071-2007  
(213) 485-1234

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered (1)	Proposed Maximum Aggregate Offering Price (1)
Deferred Compensation Obligations (2)	\$207,400,000	\$207,400,000

Edgar Filing: AMGEN INC - Form S-8

- 
- (1) Estimated solely for purposes of determining the registration fee.
  - (2) The Deferred Compensation Obligations (the "Obligations") are unsecured general obligations of Amgen Inc. to pay deferred compensation in accordance with the Amgen Nonqualified Deferred Compensation Plan.

PART I

Item 1. Plan Information

Not required to be filed with this Registration Statement.

Item 2. Registrant Information and Employee Plan Annual Information

Not required to be filed with this Registration Statement.

PART II

Item 3. Incorporation of Documents by Reference

The registrant, Amgen Inc., a Delaware corporation (the "Company"), hereby incorporates the following documents in this Registration Statement by reference:

- A. The Company's Annual Report on Form 10-K for the year ended December 31, 2000;
- B. The Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2001, June 30, 2001 and September 30, 2001;
- C. The Company's Current Report on Form 8-K filed on December 17, 2001; and
- D. Description of the Company's Common Stock, Contractual contingent payment rights and preferred share rights plan contained in the Registration Statements on Form 8-A filed with the SEC on September 7, 1983 and April 1, 1993, and the Form 8-K filed with the SEC on December 17, 2000, respectively.

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities

Not applicable.

Item 5. Interests of Named Experts and Counsel

Not applicable.

## Edgar Filing: AMGEN INC - Form S-8

### Item 6. Indemnification of Directors and Officers

Section 145 of the Delaware General Corporation Law, the Restated Certificate of Incorporation, as amended, and the Amended and Restated Bylaws of the Company contain provisions covering indemnification of corporate directors and officers against certain liabilities and expenses incurred as a result of proceedings involving such persons in their capacities as directors and officers, including proceedings under the Securities Act of 1933, as amended (the "Securities Act") and the Exchange Act.

The Company has authorized the entering into of indemnity contracts and provides indemnity insurance pursuant to which officers and directors are indemnified or insured against liability or loss under certain circumstances which may include liability or related loss under the Securities Act and the Exchange Act.

### Item 7. Exemption from Registration Claimed

Not applicable.

### Item 8. Exhibits

- 4.1\* Amgen Nonqualified Deferred Compensation Plan.
- 5.1\* Opinion of Latham & Watkins as to the legality of the obligations being registered.
- 23.1\* Consent of Ernst & Young LLP.
- 23.2\* Consent of Latham & Watkins (included in Exhibit 5.1 hereto).
- 24.1\* Powers of Attorney (included on signature page to Registration Statement).

---

\* Filed herewith.

### Item 9. Undertakings

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(a) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(b) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

## Edgar Filing: AMGEN INC - Form S-8

(c) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (1)(a) and (1)(b) shall not apply if the registration statement is on Form S-3 or Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in

the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

### SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on this 22nd day of January, 2002.

AMGEN INC.

# Edgar Filing: AMGEN INC - Form S-8

By: /s/ Kevin W. Sharer

-----  
Kevin W. Sharer  
Chairman of the Board, Chief Executive Officer and  
President

## POWER OF ATTORNEY

We, the undersigned officers and directors of Amgen Inc., and each of us, do hereby constitute and appoint each and any of Kevin W. Sharer, Richard Nanula and Steven M. Odre, our true and lawful attorney and agent, with full power of substitution and resubstitution, to do any and all acts and things in our name and behalf in any and all capacities and to execute any and all instruments for us in our names, in connection with this Registration Statement or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, including specifically, but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto; and we hereby ratify and confirm all that said attorney and agent, or his substitute, shall do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated:

Signatures -----	Title -----	Date ----
/s/ Kevin W. Sharer ----- Kevin W. Sharer	Chairman of the Board, Chief Executive Officer and President	January 22, 2002
/s/ Richard Nanula ----- Richard Nanula	Executive Vice President, Finance, Strategy and Communications, and Chief Financial Officer	January 22, 2002
/s/ Barry D. Schehr ----- Barry D. Schehr	Vice President, Financial Operations, and Chief Accounting Officer	January 22, 2002
/s/ David Baltimore ----- David Baltimore	Director	January 22, 2002
----- Frank J. Biondi, Jr.	Director	January 22, 2002

Edgar Filing: AMGEN INC - Form S-8

Signatures -----	Title -----	Date ----
/s/ William K. Bowes, Jr. ----- William K. Bowes, Jr.	Director	January 22, 20
/s/ Jerry D. Choate ----- Jerry D. Choate	Director	January 22, 20
/s/ Frederick W. Gluck ----- Fredrick W. Gluck	Director	January 22, 20
/s/ Franklin P. Johnson, Jr. ----- Franklin P. Johnson, Jr.	Director	January 22, 20
/s/ Steven Lazarus ----- Steven Lazarus	Director	January 22, 20
/s/ Gilbert S. Omenn ----- Gilbert S. Omenn	Director	January 22, 20
/s/ Judith C. Pelham ----- Judith C. Pelham	Director	January 22, 20
/s/ J. Paul Reason ----- J. Paul Reason	Director	January 22, 20
/s/ Donald Rice ----- Donald Rice	Director	January 22, 20
----- Patricia C. Sueltz	Director	January 22, 20

EXHIBIT INDEX

Exhibit Number -----	Description -----
4.1*	Amgen Nonqualified Deferred Compensation Plan.
5.1*	Opinion of Latham & Watkins regarding the legality of the obligations being registered.
23.1*	Consent of Ernst & Young LLP.
23.2*	Consent of Latham & Watkins (included in opinion filed as Exhibit 5.1 hereto).

Edgar Filing: AMGEN INC - Form S-8

24.1\*            Power of Attorney (included on signature page to Registration Statement).

---

\* Filed herewith.